Advancing the Cutting Edge of Cancer Care
While cancer care has already made tremendous progress, further innovation and research are necessary to develop and implement the next generation of therapeutics, best practices, disease preventions and specialized treatments targeted to the precise needs of the patient. Investigative research, including both “wet” translational and laboratory research as well as “dry” population health and value-based research, provides the ability to identify, develop and study new innovations in a real health system setting. The AdventHealth Cancer Institute participates in approximately 175 clinical trials each year, making it one of the most active sites for this kind of research in all of Florida.
Recent News
Upcoming Events
-
GI Oncology Symposium 2024
Details TBD
AdventHealth Clinicians in the News
Highlighted Cancer Trials
Through cancer trials, we hope to find new ways to improve patients’ cancer treatments and quality of life. Our clinical trials provide access to innovative and experimental therapies to patients with solid and circulating tumors, including through the National Cancer Institute’s Clinical Trials Network (NCTN). Our centralized clinical research team is comprised of research nurses, data managers, research assistants and regulatory coordinators.
-
Now Enrolling
Phase 3 Randomized Study of Talazoparib with Enzalutamide in Men with DDR Gene Mutated mCSPC
Principal Investigator: Carlos Alemany, MD
-
Now Enrolling
A Randomized Phase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRAS G12C Mutation with Disease Progression On or After Standard First-Line Therapy
Principal Investigator: Mohamedtaki Tejani, MD
-
Now Enrolling
A Randomized, Multicenter, Double-blind, Placebo-controlled Phase 3 Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Patients With High-risk, Estrogen Receptor Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer (CheckMate 7FL: CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 7FL)
Principal Investigator: Carlos Alemany, MD
Our Accreditations and Rankings
Having confidence is the first step in your patient treatment journey. We’re honored to be recognized for delivering the highest standard of excellence across the full spectrum of cancer care.